

ASX Code: PSY

10 November 2014

Panorama Synergy Appoints Specialist Biosciences Adviser

Panorama Synergy Limited [ASX: PSY] (“Panorama” or the “Company”) announces that it has appointed Dr Stewart Washer as a specialist Biosciences Adviser to the Company, with immediate effect.

Dr Washer has considerable experience in the healthcare arena. A doctor by qualification and an Immunologist by speciality, Dr Washer is excited by the potential of Panorama’s LumiMEMS™ Reader to open up new opportunities in healthcare, from in hospital bedside patient care pathology, to wearable medical devices and environmental monitoring and response.

Dr Washer will assist the Company’s management team and scientists at the University of Western Australia (UWA) with the development of products applicable to the healthcare market which incorporate Panorama’s unique optical readout technology for MEMS sensors.

The Company will make further appointments to enhance it’s specific industry knowledge, as it enters the large numbers of markets where it’s technology is applicable, knowing it cannot be expert in each.

Dr Stewart Washer commented:

“We face a new era in patient treatment arising from digital health and regenerative medicine. This will change the way we diagnose, manage and treat disease and maintain people’s health.

Panorama is uniquely positioned to be a lead innovator in digital health by applying their MEMS technology to develop new sensors that measure key indicators of health and disease. I look forward to working with them in this exciting frontier.”

Terry Walsh, Managing Director of Panorama, said:

“We are delighted to have Stewart on board. He recognises the remarkable potential of the LumiMEMS™ Reader technology in promoting healthcare services in ways we have all dreamed of for a long time. His specialist knowledge and extensive experience of bringing together medicine and technology to provide healthcare advances will be key in guiding Panorama Synergy’s activities.”

Dr Stewart Washer – Biography Snapshot

Dr Washer has 20 years of CEO and Board experience in healthcare and medical technology, biotech and agrifood companies. His current Chairmanships include:

- Orthocell Ltd (ASX: OCC): a company focused on the regeneration of tendon, cartilage and the repair of soft tissue injuries
- Cynata Therapeutics Ltd (ASX: CYP): a developer of stem cell therapies and regenerative medicine
- Minomic International Ltd: a developer of accurate, non-invasive tests for prostate cancer
- Firefly Health Innovations: currently conducting clinical trials on a low-cost dental diagnostic solution



Panorama Synergy Ltd
ACN 060 369 048

About Panorama Synergy

Panorama Synergy is a Perth-based technology company focused on the commercial and technological advancement of its optical readout system for MEMS, the LumiMEMS Reader™.

In partnership with UWA, Panorama's unique technology has been developed by a team of renowned scientists led by Gino Putrino, the chief architect of the MEMS optical readout system. The Company has an exclusive worldwide licensing agreement with the UWA for optical technologies related to MEMS sensors.

The company's Board includes Managing Director, Terry Walsh and Aidan Montague, Chairman, and Director Jeff Braysich. Mr Walsh and Mr Montague have extensive backgrounds in high technology. Mr Walsh was formerly Managing Director for Cisco Australia and New Zealand for five years and then CEO of Cisco Canada for the subsequent five years. Mr Montague served in various roles in Europe, was CEO of Cisco in South Africa, and as Director of Strategic Alliances for Cisco in Asia Pacific. Mr Braysich has extensive experience in the Capital Markets, working as a stockbroker, operating a Financial Services business and serves on various Boards.

As previously announced, Dr Jason Chaffey will be joining the Board on November 17th. Dr Chaffey has a PhD in MEMS and a successful track record of commercialising MEMS technology

About MEMS

MEMS is an umbrella term used to describe a miniature device which integrates mechanical and electrical elements designed to work together to sense and report on the physical properties of their immediate or local environment, or, when signalled to do so, to perform a controlled physical interaction or actuation with their immediate or local environment.

MEMS sensors are used to detect the presence or absence of chemical and biological substances. They can be used to detect anything from explosives at an airport to the presence of certain types of cancer from your breath.

The current MEMS market is estimated to be \$14 billion in 2014, growing to over \$22 billion by 2018 according to a Yole Development report called "Status of the MEMS Industry", July 2013.

For further information contact:

Panorama Synergy
Terry Walsh, Managing Director
Tel: +61 2 8226 3377